Structures by: Lazar S.
Total: 9
Methyl 2-(3-oxo-3,4-dihydro-2<i>H</i>-1,4-benzothiazin-4-yl)acetate
C11H11NO3S
Acta Crystallographica Section E (2011) 67, 3 o724
a=17.347(5)Å b=8.724(2)Å c=7.2740(10)Å
α=90.00° β=98.71(2)° γ=90.00°
3-Methyl-1-(prop-2-en-1-yl)quinoxalin-2(1<i>H</i>)-one
C12H12N2O
Acta Crystallographica Section E (2010) 66, 7 o1767
a=5.0722(5)Å b=13.4707(13)Å c=15.0507(13)Å
α=90.00° β=95.082(5)° γ=90.00°
2-Methyl-3-(<i>n</i>-octylsulfanyl)quinoxaline
C17H24N2S
Acta Crystallographica Section E (2010) 66, 4 o992
a=7.3514(3)Å b=8.2978(3)Å c=14.2168(5)Å
α=92.275(2)° β=98.706(2)° γ=103.810(2)°
1-Benzyl-3-methylquinoxalin-2(1<i>H</i>)-one
C16H14N2O
Acta Crystallographica Section E (2010) 66, 8 o1922
a=7.4433(2)Å b=17.5444(5)Å c=18.0598(7)Å
α=118.034(2)° β=100.217(2)° γ=92.7260(10)°
3,4,6-Trimethyl-1-phenyl-1<i>H</i>-pyrazolo[3,4-<i>b</i>]pyridine
C15H15N3
Acta Crystallographica Section E (2010) 66, 8 o1966
a=7.1714(2)Å b=12.0690(4)Å c=14.5491(5)Å
α=90.00° β=101.2510(10)° γ=90.00°
3-[2-(1<i>H</i>-Benzimidazol-2-ylsulfanyl)ethyl]-1,3-oxazolidin-2-one
C12H13N3O2S
Acta Crystallographica Section E (2010) 66, 12 o3137
a=8.2580(10)Å b=10.0740(10)Å c=29.201(3)Å
α=90.00° β=90.00° γ=90.00°
<i>rac</i>-(3<i>S</i>,4<i>S</i>)-3-Hydroxy-4-phenyl-1-[(<i>S</i>)-(3-phenyl- 4,5-dihydro-1,2-oxazol-5-yl)methyl]-4,5-dihydro-1<i>H</i>-1,5-benzodiazepin- 2(3<i>H</i>)-one
C25H23N3O3
Acta Crystallographica Section E (2011) 67, 4 o945-o946
a=8.981(2)Å b=9.044(2)Å c=13.6850(10)Å
α=95.373(10)° β=102.433(10)° γ=100.03(2)°
6-Nitro-2,3-dihydro-1<i>H</i>-pyrrolo[2,1-<i>c</i>][1,4]benzodiazepine- 5,11(10<i>H</i>,11a<i>H</i>)-dione
C12H11N3O4
Acta Crystallographica Section E (2011) 67, 8 o2003
a=10.7364(2)Å b=6.89250(10)Å c=16.3901(3)Å
α=90.00° β=101.8700(10)° γ=90.00°
(<i>Z</i>)-1,3-diallyl-4-(2-oxopropylidene)-4,5-dihydro-1<i>H</i>-1,5- benzodiazepin-2(3<i>H</i>)-one
C18H20N2O2
Zeitschrift für Kristallographie - New Crystal Structures (2008) 223, 4 435
a=8.889(4)Å b=9.062(2)Å c=11.0870(10)Å
α=111.270(10)° β=94.91(2)° γ=104.80(3)°